Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Buys Additional Alnylam Stock

Premium

Alnylam Pharmaceuticals announced this week that its partner Genzyme has exercised an option to buy 344,448 unregistered shares of Alnylam stock for $23 million as part of the companies broad genetic diseases alliance disclosed earlier this year.

In January, the companies announced that they had signed a deal under which Genzyme acquired the rights to Alnylam's existing and future genetic diseases medicines programs in territories outside of North America and Western Europe for the next six years.

In exchange, Genzyme purchased a 12 percent stake in Alnylam, buying about $700 million shares of newly issued stock at $80 apiece. Following Alnylam's issuance of stock to Merck in exchange for that company's RNAi assets, Genzyme was given the option to buy additional Alnylam stock in order to maintain its ownership percentage.

Genzyme exercised the option, buying the additional shares at $66.88 each, the closing price of Alnylam's stock at the time.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.